The availability of large quantities of highly purified recombinant interleukin 11 (rhulL-11) has allowed us to investigate the effects of rhuIbll on sheep red blood cell (SRBC)-specific antibody responses in the routine system. The results showed that rhuII~11 was effective in enhancing the generation of mouse spleen SRBC-specific plaque-forming cells (PFC) in the in vitro cell culture system in a dose-dependent manner. These effects of rhuIL-11 were abrogated completely by the addition of anti-rhulbll antibody, but not by the addition of preimmunized rabbit serum. Cell-depletion studies revealed that L3T4 (CD4) + T cells, but not Lyt-2 (CD8) + T cells, are required in the rhuIL-11-stimulated augmentation of SRBC-specific antibody responses. The effects of rhulL-11 on the SRBC-specific antibody responses in vivo were also examined. Rhulbll administration to normal C3H/HeJ mice resulted in a dose-dependent increase in the number of spleen SRBC-specific PFC as well as serum SRBC-specific antibody titer in both the primary and secondary immune responses. In mice immunosuppressed by cyclophosphamide treatment, rhuIbll administration siguificantly augmented the number of spleen SRBC-specific PFC as well as serum SRBC-specific antibody titer when compared with the cyclophosphamide-treated mice without II.,11 treatment. These results demonstrated that IL,11 is a novel cytokine involved in modulating antigen-specific antibody responses in vitro as well as in vivo.
G
rowth and differentiation of B lymphocytes are regulated at least in part by many soluble factors called cytokines that are produced by a variety of cells (1) (2) (3) . Although the exact number of cytokines and the precise mechanisms of cytokine action involved in this process are still under intensive investigation, a number of cytokines such as II:2 (4-6), IL4 (7), Ib5 (8, 9) , Ib6 (5, 6, 10, 11) , IFN-,y (7, 12) , and Ibl0 (13) have been implicated to play an important role in modulating B cell activation, proliferation, and/or differentiation.
Recently, a new cytokine designated as IL-11 was identified in medium conditioned by a ceU line derived from primate bone marrow stromal cells (14) . The cDNA encoding primate IL-11 was cloned by expression cloning method based on the ability of this cytokine to stimulate the proliferation of an Ib6-dependent mouse plasmacytoma cell line, Tl165 (14) . The human homologue of primate IL,11 was subsequently cloned and expressed in mammalian cells (14) . Initial studies have shown that Ibll is able to increase the number of antibody-forming cells in murine spleen cell cultures and to augment Ib3-dependent development of megakaryocyte colonies in both human and mouse bone marrow cultures. Recent studies have also shown that recombinant human IL-11 (rhulL-11), like IL-6, can bring the pluripotent stem calls out of the Go stage of the cell cycle to respond to intermediate or late-acting growth factors such as IL-3 or granulocyte/macrophage CSF (15) . These results imply that rhuIbll 1 is likely to be a multifunctional mediator in the complicated cytokine network.
Since many biological activities of Ibll overlapped with those of Ib6, and IL-6 has been shown to play an important role in modulating immune responses, we speculated that Ibll may also contribute to the immunologic events critical to the host defense system. As a first step of understanding the role of ILl1 in regulating immune responses, we tested the effects of rhuIL-11 on antigen (Ag)-specific antibody responses in vitro and in vivo. The results demonstrated that Ibll significantly enhanced in vitro Ag-specific antibody responses and augmented Ag-specific antibody responses in both normal mice and mice immunosuppressed by cyclophosphamide (CYC) treatment.
Materials and Methods
M~:~ C57BL/6J and C3H/HeJ female mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Mice aged 8-12 wk were used in all the experiments.
RhulL-11. Rhulb11 produced in Esckerickia coli and purified to homogeneity was obtained from Genetic Institute (Cambridge, M_A). Purified rhulL-11 had a specific activity of 1.8 x 106 U/mg by Tl165 cell proliferation assay (14) and contained <1.25 ng endotoxin/mg protein.
Antibodies. Anti-Thy-l.2 mAb, anti-L3T4 mAb, and anti-Lyt-2 mAb were purchased from Cedarlane Lab (Ontario, Canada). Polyclonal rabbit anti-rhulL-11 antiserum was a generous gift from Dr. Ed Alderman (Genetics Institute).
Cell Preparation. To deplete CD3 +, CD4 +, or CD8 + cells, routine spleen cells were incubated with anti-Thy-l.2 mAb, anti-L3T4 mAb, or anti-Lyt-2 mAb in RPMI 1640 supplemented with 0.5% BSA, 100 U/ml penicillin, 100 #g/ml streptomycin, 2 mM r-glutamine, and 5 x 10 -5 M B-mercaptoethanol (hereafter referred to as treated medium). After a 1-h incubation at 4~ cells were washed three times in treated medium and resuspended in treated medium containing 1:15 dilution of rabbit complement (Cedarlane Lab). After incubation at 37~ for 40 min with complement, cells were washed three times in treated medium and resuspended in IMDM (Sigma Chemical Co., St. Louis, MO) supplemented with 10% FCS (Hyclone, Logan, UT), 100 U/ml penicillin, 100 #g/ml streptomycin, 2 mM r-glutamine and 5 x 10 -s M ~-mercaptoethanol (hereafter referred to as complete culture medium). 
Assay for SRBC-Specific PFC In Vitra

Determination of SRBC-Specific PFC and Antibody Titer In Vivo.
SRBC were washed three times, resuspended in pyrogen-free PBS, and inoculated intraperitoneally at 2 x 106 (for secondary response) or 4 x 107 (for primary response)/0.2 ml/mouse. On the same day of antigen inoculation, groups of three mice received injections twice daily (once intraperitoneally, once subcutaneously) with 0.2 ml/mouse of 2.5% syngeneic mouse serum in PBS containing various concentrations of rhulb11 for 6 d. Control mice received the same volume of solution without IL-11. At 7 d, mice were killed, spleen cells and serum collected, and SRBC-specific PFC were assayed as described above. Anti-SRBC-specific antibody titer in serum was measured by a hemagglutination test (6) . Briefly, 50/~1 of a twofold serial dilution of mouse immune serum was mixed with 50 #1 of 1% SRBC suspension containing 1% BSA in PBS. The agglutination titer was determined after a 6-h incubation at 4~ as the reciprocal of the highest dilution giving distinct agglutination.
CYC Treatment. CYC (Sigma) was dissolved in pyrogen-free saline and injected intraperitoneally at a dose of 200 mg/kg body weight. 4 h after CYC treatment, each mouse received 4 x 107 SRBC intraperitoneally. RhulL-11 (1-/~g/injection, once intraperitoneaUy, once subcutaneously) or control solution treatment began
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Enhancement of Antigen-specific the next day and continued for the duration of the experiment. At various times, groups of three mice were killed and splenic PFC as well as serum antibody titer were determined as described above.
Measurement of Total lg Concentration in Serum.
The total amount of Ig in mouse serum was determined by ELISA as described by Luzuy et al. (18) .
Statistical Analysis. Statistical significance was assessed by the
Student's t test. Probabilities were calculated by two-tailed analysis.
Results and Discussion
Effect of rhulI.,ll on the Primary Immune Response to SRBC.
We examined the effect of purified rhulL-11 on the primary immune response to SRBC of spleen cells from C57BL/6J mice. Mouse spleen cells were cultured with SRBC in the presence of various concentrations of rhulL-11. Specific direct PFC were counted on day 5, previously determined to be the optimal period for the PFC responses (our unpublished results). As shown in Fig. 1 , rhulL-11 induced IgM PFC response in a dose-dependent manner. The addition of as low as 1 U/ml rhulbll could increase IgM PFC 3.3-fold.
At the concentration of 500 U/ml, rhulL-11 increased IgM PFC 6.7-fold. These results suggested that rhulL-11, like I1:6 (6), is a strong inducer of SRBC-specific PFC in vitro. In addition, the kinetic studies showed that the addition of rhulL-11 48 h after the initiation of spleen cell culture failed to increase Ag-specific PFC (data not shown), suggesting that rhulb11, unlike IL-6 (6), has to be added at an early stage of cell culture in order to elevate Ag-specific PFC.
Effect of rhulbll on the Immune Response to SRBC Using Spleen Cells from SRBC-Primed Mice.
As rhulb11 is an effective enhancer of SRBC-specific IgM PFC in the primary immune response, we next examined whether rhulbll augments the in vitro response to spleen cell primed with SRBC Ag in vivo. Mice were immunized intraperitoneally with 4 x 107 SRBC/mouse. 2 d after immunization, spleen cells were removed and restimulated in vitro with SRBC in the presence of rhulI~11. On day 4 (previously determined to be the 
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Effect of rhulbll on in vivo SRBC-primed spleen cell reoptimal period for the PFC response), SRBC-specific PFC were assayed. It was demonstrated that rhulL-11 augmented IgM PFC in a dose-dependent manner when spleen cells from SRBC-immunized mice were used (Fig. 2) . However, SRBCprimed spleen cells cultured in vitro without SRBC restimulation failed to respond to rhulL-11 in eliciting the SRBCspecific PFC response (data not shown). These results indicated that rhulbll could not induce the differentiation of antigen-primed B cells to become antibody-producing cells without antigen restimulation. The kinetic studies using in vivo primed spleen cell culture system showed that rhulL-11, unlike Ib6 (6), has to be added at an early stage of cell culture in order to significantly augment Ag-specific PFC. 
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Abrogation of rhulL11-induced Augmentation of SRBC-specific PFC Responses by anti-rhull_,11
Antibody. To demonstrate r h u l b l l as an enhancer of SR.BC-spedfic PFC, the effect of anti-rhulL-11 antibody on the rhulL-11-induced augmentation of SILBC-specific PFC was examined. Addition of 50 neutralization units of anti-rhulL-11 antibody totally abolished the capacity of rhulL-11 to increase the production of SP, BC-specific PFC (Fig. 3) , whereas the addition of same concentration of preimmunized rabbit serum had no effect and secondary (~ response. Mice sera were obtained from the primary and secondary response to SRBC in vivo as indicated above. Serum anti-SRBC-specific antibody titers were then measured by hemagghtination test as described in Materials and Methods. The data expressed as stimulation index (defined as the anti-SRBC titer in treated mice/anti-SRBC titer in control mice) are the arithmetic means of three individually assayed mice per group. Two additional experiments showed similar results.
on the enhancement of SRBC-specific PFC response by rhuIb11. RhulL-11 injection and assay for PFC as well as serum antibody titer were determined as described in Materials and Methods. It was found that rhuIL-11 strongly enhanced the Ag-specific antibody response in a dose-dependent fashion (Fig. 5, B and C) . At the concentration of 4/zg/mouse/d, rhuIb11 increased SRBC-specific IgM PFC eight-and IgG PFC fourfold, and serum SRBC-specific antibody titer 10-fold, respectively. These results are comparable with the results obtained in the II.-6 system (6). However, the effects of IL-11 on Ag-specific antibody responses in the primary response in vivo (Fig. 5 , A and C) may be different from those of Ib6 (6) We also observed that administration of rhullr (4 /~g/mouse/d for 6 d) did not significantly enhance the SRBCspecific PFC response or increase the total Ig content in mice that did not receive a secondary SRBC injection when compared with the control. Furthermore, SRBC-specific PFC in spleen and total Ig concentration in serum were not significantly enhanced by the administration of rhulbll into normal mice without Ag stimulation. These results demonstrated that rhulL-11 is not a polyclonal activator under our experimental conditions. However, we do not rule out the possibility that IDll may be a polyclonal activator at very high concentration since it has been reported that II.-6 is a very effective polyclonal activator in vivo when tested at high concentration (22, 23) . These questions will be addressed by using the II.,11 transgenic mouse model.
Effect of Depletion of T Cells from
Effect of rhulLll Administration on Restoration of Impaired Antibody Responses in CYC-treated
Mice. In addition to its ability to augment in vivo Ag-specific antibody response in normal mice, we also assessed the ability of rhulb11 to stimulate the regeneration of Ag-specific antibody-forming cells in C3H/HeJ mice with CYC-induced lymphopenia. As shown in Fig. 6, A and B, the spleen SRBC-specific PFC response and serum anti-SRBC antibody titer of the CYC-treated mice that received rhull.-11 injection were significantly enhanced at all time points when compared with the control CYCtreated mice. For example, CYC-treated mice with IDll administration at day 12 had 4.5-fold higher spleen SRBC-specific PFC and sixfold higher serum anti-SRBC antibody titer than control mice without II.-11 injection. This result suggests that rhulL.11 may play an important role in stimulating the recovery of impaired Ag-specific antibody response in CYC-treated mice and Ibll may have important therapeutic potential specifically to stimulate the regeneration of decreased Ag-specific humoral immune responses induced by CYC treatment.
The major concern in these in vivo experiments is the possible role of contaminating endotoxin in the Ag-specific antibody responses. RhulL-11 used in these studies contained <1.25 ng endotoxin/mg protein of rhulL-11. This very low concentration of endotoxin did not affect the Ag-specific humoral immune responses in the endotoxin-resistant C3H/HeJ mice. Therefore, the possibility that endotoxin contaminant might account for the observed rhulL-11 effect in increasing Ag-specific antibody responses in vivo can be reasonably excluded.
In conclusion, the results presented here demonstrated that rhulb11 is a novel cytokine involved in modulating Ag-speciflc antibody production in vivo and in vitro in normal mice. In addition, administration of I1.-11 into mice after chemicalinduced lymphopenia significantly stimulates the reconstitution of decreased Ag-specific antibody-forming cells in CYCtreated C3H/HeJ mice. Although the mechanism by which IDll exerts its action in vivo is not clear at the present time, these data suggest that rhulL-11 may be potentially useful as an therapeutic agent in enhancing humoral immune response under certain clinical situations where accelerated lymphoid functions might be beneficial.
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